The State of Cancer Care in America: 2016 report, to be released on March 15 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.
Understanding and integrating patients’ cultural beliefs into cancer treatment plans may help improve their acceptance of and adherence to treatment in multicultural settings. Researchers examined traditional Maya healers’ understanding of cancer and published their findings online today in the Journal of Global Oncology.
An innovative service model that partners radiation oncology with palliative care leads to better results for patients, according to a new analysis. The model of care, established at Mount Sinai Medical Center in New York, is one of only a handful in the country.
A new guidance statement from the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine is being presented for the first time at the 2015 Palliative Care in Oncology Symposium in Boston.
ALEXANDRIA, Va. – A new study provides compelling evidence that a simple tool can help predict which patients with cancer may be in their final year of life. The tool, known as the Surprise Question, was found to predict the risk of cancer death within one year better than factors such as cancer type or stage alone. This study will be presented at the upcoming 2015 Palliative Care in Oncology Symposium in Boston.
An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 finds a notable increase in higher-risk cases of the disease between 2011 and 2013. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA >10ng/ml or Gleason score 7 or clinical stage T2b/2c) had a nearly four-fold higher chance of dying from prostate cancer within 15 years. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
ALEXANDRIA, Va. – Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.
An analysis of five large, prospective cohort studies indicates that lung (stage I), bladder, kidney and head and neck cancer survivors who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to five-fold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked. The association between smoking and developing a second primary smoking-associated cancer was similar to the association between smoking and developing a first primary smoking-associated cancer (patients who smoked more than 20 cigarettes per day had a 5.41-fold higher risk of developing cancer than individuals who have never smoked). Notably, current smoking at any level increased the risk of overall mortality across all cancer disease sites. The study, published on November 10 in the Journal of Clinical Oncology, affirms the 2014 Surgeon General report’s conclusion that patients and survivors who smoke are at a higher risk of developing a
Researchers in Germany report that nearly a third of more than 2,100 patients with cancer interviewed at inpatient and outpatient care centers experienced a clinically meaningful level of mental or emotional distress that meets the strict diagnostic criteria for mental disorders including anxiety, depressive and adjustment disorders during the prior four weeks. The prevalence of these issues varied by cancer type. The highest prevalence was found among patients with breast cancer (42%) and head and neck cancer (41%), followed by malignant melanoma (39%). The lowest prevalence was seen among patients with prostate cancer (22%), stomach cancers (21%), and pancreatic cancer (20%). The study — the largest to date assessing the mental and emotional health of patients with cancer using a fully standardized, diagnostic face-to-face interview — is published in the October 6 issue of the Journal of Clinical Oncology.
A new, large cohort analysis from the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, indicates that men who had moderate baldness affecting both the front and the crown of their head at age 45 were at a 40% increased risk of developing aggressive prostate cancer (usually indicates a faster growing tumor resulting in poorer prognosis relative to non-aggressive prostate cancer) later in life, compared to men with no baldness. There was no significant link between other patterns of baldness and prostate cancer risk. The study, published September 15 in the Journal of Clinical Oncology, supports earlier research suggesting that male pattern baldness and prostate cancer may be linked.
CHICAGO – New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body’s immune response to the disease.
Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO’s Plenary session, which features the meeting’s most important clinical cancer research with the greatest potential to impact patient care.
Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO’s Plenary session, which features the meeting’s most important clinical cancer research with the greatest potential to impact patient care.
Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments.
Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers.
The findings of a large international prospective study published in the Journal of Clinical Oncology suggest for the first time that women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35, as waiting until a later age appears to increase the risk of ovarian cancer before or at the time of the preventive surgery. Women with a BRCA2 mutation, however, do not appear to be at an increased risk by age 35, suggesting they may delay this procedure until later. Moreover, women with BRCA1 and BRCA2 mutations who had this surgery experienced a 77 percent reduction in their overall risk of death by age 70.
Research on the latest approaches for the diagnosis, treatment, and management of GI cancers was released today in advance of the 2014 Gastrointestinal Cancers Symposium being held January 16-18, 2014, at The Moscone West Building in San Francisco, CA.
ALEXANDRIA, Va. — Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology (ASCO). The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.
New results from a prospective study published in the Journal of Clinical Oncology show that patients with a body mass index (BMI) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with healthy weight patients, even after adjusting for factors that are known to predict survival for patients with this disease, such as age and disease stage.
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) today issued a joint, updated guideline aimed at improving the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer.
New results from a large retrospective study of the National Cancer Institute’s SEER database show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found that married patients are more likely to be diagnosed with earlier-stage disease and much more likely to receive the appropriate therapy. This study is the first to show a consistent and significant benefit of marriage on survival among each of the ten leading causes of cancer-related death in the United States ─ lung, colorectal, breast, pancreatic, prostate, liver/bile duct, non-Hodgkin lymphoma, head and neck, ovarian, and esophageal cancer.
Five additional studies of note are among those that will be presented at the 2013 Breast Cancer Symposium, taking place September 7-9, 2013 at the San Francisco Marriott Marquis in San Francisco, California. Two studies examine cognitive function in women who undergo treatment for early-stage breast cancer; a third evaluates impact of tumor genotyping on clinical trial enrollment; and the final two evaluate the outcomes of different treatment approaches.
New studies exploring breast cancer risk perceptions and use of radiotherapy and MRI for women with ductal carcinoma in situ (DCIS, a preinvasive form of breast cancer) were highlighted today in a virtual presscast in advance of the 2013 Breast Cancer Symposium. The Symposium will take place September 7-9, 2013, at the San Francisco Marriott Marquis in San Francisco.
Today, Symposium co-sponsors announced the research to be included in the 2013 Breast Cancer Symposium Press Program. The three key studies will focus on advances in breast cancer risk, detection and treatment. Study details will be presented in an embargoed presscast for reporters on Wednesday, September 4, 2013, from 12:00-1:30 PM (EDT). ASCO expert in breast cancer Steven O’Day, MD will moderate the presscast which will feature researchers from each of the studies.
Summary of a retrospective study being published online April 22, 2013 in the Journal of Clinical Oncology, reports that certain HER2 targeted drugs may benefit patients with advanced lung cancer who carry rare mutations in the HER2 protein.
A study analyzing the impact of the Delaware Cancer Consortium, the state's cancer control program, reports a 41 percent reduction in colorectal mortality rates for African Americans. The study, published April 15 in the Journal of Clinical Oncology, provides analysis on a novel design and approach used to eliminate colorectal cancer disparities for the first time by a state cancer control program.
Summary of a study being published online April 8, 2013 in the Journal of Clinical Oncology, reports that adding cetuximab (Erbitux) to chemotherapy enabled previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis
Summary of a study being published online March 25, 2013 in the Journal of Clinical Oncology, reports that Chinese women who consumed more soy before being diagnosed with lung cancer lived longer compared with those who consumed less soy.
The American Society of Clinical Oncology and the Conquer Cancer Foundation invite you to a moderated discussion of progress toward a "learning health system" that will transform cancer care and speed the search for cures.
An analysis of self-reported data from outpatient oncology practices that participated in the American Society of Clinical Oncology’s Quality Oncology Practice Initiative (QOPI®) found a significant increase in performance on quality measures for oncology care over a four-year period, especially in adopting new clinical practices. The study was published on March 11, in the Journal of Clinical Oncology.
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.
Research on promising new therapies and data on the relative benefits of established treatments for genitourinary cancers were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 14-16, 2013, at the Rosen Shingle Creek in Orlando, FL.
New research into the treatment and prognosis of gastrointestinal cancers was released today in advance of the tenth annual Gastrointestinal Cancers Symposium being held January 24-26, 2013, at The Moscone West Building in San Francisco, CA.
Three key studies from the 2013 Genitourinary Cancers Symposium will be featured in an embargoed presscast for reporters on Tuesday, February 12, 2013, from 12:00-1:30 PM (EST). These important studies will focus on the latest advances being made in the screening and management of several genitourinary cancers. The presscast will be moderated by Bruce J. Roth, MD, a member of the 2013 Genitourinary Cancers Symposium News Planning Team and chair of ASCO’s Cancer Communications Committee.
Five noteworthy studies from the 2013 Gastrointestinal Cancers Symposium will be featured in an embargoed presscast for reporters on Tuesday, January 22, 2013, from 12:00-1:30 PM (EST). Highlighted studies will focus on the latest advances being made in the screening and treatment of several gastrointestinal cancers. The presscast will be moderated by Neal Meropol, MD, a gastrointestinal cancers expert and member of the 2013 Gastrointestinal Cancers Symposium News Planning Team and ASCO’s Cancer Communications Committee.
The American Society of Clinical Oncology (ASCO) has just released its annual report on the top cancer advances of the year. Clinical Cancer Advances 2012: ASCO’s Annual Report on Progress Against Cancer highlights major achievements in precision medicine, cancer screening and overcoming treatment resistance.
Five additional studies to be presented at the 2012 Quality Care Symposium provide insight on how oncology practices can improve the quality of care they provide. The Symposium will take place November 30 – December 1, at the Manchester Grand Hyatt in San Diego.
New studies released today reveal important advances in cancer care quality measurement, physician adherence to quality standards, and end-of-life care, while highlighting the overuse of contralateral prophylactic mastectomy. The studies were released in a presscast today in advance of ASCO’s inaugural 2012 Quality Care Symposium. The Symposium will take place November 30 – December 1, 2012, at the Manchester Grand Hyatt in San Diego.
A large population- and health systems-based prospective study reports earlier discussions about end of life (EOL) care preferences are strongly associated with less aggressive care in the last days of life and increased use of hospice care for patients with advanced cancer. The study, published November 13 in the Journal of Clinical Oncology, provides the first-of-its-kind scientific evidence that timing of EOL care discussions affects decisions about EOL care.
Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium. The Symposium will take place September 13-15, 2012, at the San Francisco Marriott Marquis in San Francisco.
The American Society of Clinical Oncology (ASCO) today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO’s 47th Annual Meeting.
Summary of a study being published online March 12, 2012 in the Journal of Clinical Oncology, reporting that five- and 10-year survival increased steadily among children and teenagers treated for acute lymphoblastic leukemia (the most common type of pediatric cancer) between 1990 and 2005, as part of Children's Oncology Group clinical trials. Similarly, death rates from ALL fell by 30 to 50 percent during the study period.
Summary of a study being published online February 27, 2012 in the Journal of Clinical Oncology, showing that women who underwent a once-common chemotherapy regimen known as CMF between 1976 and 1995 score slightly lower on cognitive tests that measure word learning, memory and information processing speed than women without a history of cancer.
Summary of the first prospective study – published online February 13, 2012 in the Journal of Clinical Oncology – to provide strong evidence of increased breast and pancreatic cancer risk in individuals with Lynch syndrome, who carry certain inherited genetic mutations in DNA repair genes. The study is also the first to show that relatives of people with Lynch syndrome who do not carry these mutations have no increased risk of cancer
Research on promising new therapies and data on the relative benefits of established treatments for prostate cancer were released today, in advance of the fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, Calif.
New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right